Literature DB >> 22705088

Response surface methodology to determine optimal measles-specific cytokine responses in human peripheral blood mononuclear cells.

Matthew J Taylor1, Iana H Haralambieva, Robert A Vierkant, Inna G Ovsyannikova, Gregory A Poland.   

Abstract

Limitations of assay variability, labor costs, and availability of cells can affect the conduct of large population-based studies. The ability to determine optimal conditions for laboratory assessment of immune outcomes, including measurement of cytokines, can reduce the number of peripheral blood mononuclear cells (PBMCs) needed, reduce the labor costs involved, and the variability in secreted cytokine response by pooling cytokines from the same cell culture supernatant. Previously, we used response surface methodology to predict optimal conditions for vaccinia virus-stimulated cytokine responses in recipients of smallpox vaccine. Here, we apply the same approach for a measles vaccine study. PBMCs were collected from vaccinated subjects, and seven cytokines (IFN-γ, IL-2, TNF-α, IL-10, IFN-α, IFN-λ1, and IL-6) involved in measles virus-specific cytokine immune responses were examined. PBMCs were stimulated with differing multiplicity of infection (MOI) and days in culture (incubation time). Response surface methodology was used to select the optimal MOI and incubation time for each secreted cytokine. Our results demonstrate that each cytokine's optimal conditions (MOI and incubation time) differ for each virus (measles vs. vaccinia) and each cytokine's optimal conditions for each virus can be predicted using response surface methodology. These conditions allow for cytokines with overlapping optimal conditions to be pooled from the same supernatant in culture to reduce the number of PBMCs used, the costs involved, and assay variability. Therefore, response surface methodology is an effective technique that can be used to optimize antigen-specific secreted cytokines prior to population-based studies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22705088      PMCID: PMC3399242          DOI: 10.1016/j.jim.2012.06.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay.

Authors:  Chad A Ray; Carmen Dumaual; Mark Willey; Jeffrey Fill; Peter J O'Brien; Ian Gourley; Viswanath Devanarayan; Robert J Konrad
Journal:  J Pharm Biomed Anal       Date:  2006-04-11       Impact factor: 3.935

2.  Sequential ELISA to profile multiple cytokines from small volumes.

Authors:  Marcin F Osuchowski; Javed Siddiqui; Shannon Copeland; Daniel G Remick
Journal:  J Immunol Methods       Date:  2005-07       Impact factor: 2.303

3.  Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

4.  Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination.

Authors:  N Dhiman; I G Ovsyannikova; J E Ryan; R M Jacobson; R A Vierkant; V S Pankratz; S J Jacobsen; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

5.  Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees.

Authors:  Neelam Dhiman; Iana H Haralambieva; Robert A Vierkant; V Shane Pankratz; Jenna E Ryan; Robert M Jacobson; Inna G Ovsyannikova; Gregory A Poland
Journal:  Cytokine       Date:  2010-02-01       Impact factor: 3.861

6.  Response surface methodology to determine optimal cytokine responses in human peripheral blood mononuclear cells after smallpox vaccination.

Authors:  Jenna E Ryan; Neelam Dhiman; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  J Immunol Methods       Date:  2008-11-25       Impact factor: 2.303

7.  Cytokine production patterns and antibody response to measles vaccine.

Authors:  Inna G Ovsyannikova; Karlene C Reid; Robert M Jacobson; Ann L Oberg; George G Klee; Gregory A Poland
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

8.  Optimal kinetics for quantification of antigen-induced cytokines in human peripheral blood mononuclear cells by real-time PCR and by ELISA.

Authors:  Slavka Listvanova; Stéphane Temmerman; Patrick Stordeur; Virginie Verscheure; Sammy Place; Lin Zhou; Camille Locht; Françoise Mascart
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

9.  Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models.

Authors:  Shih-Houng Young; James M Antonini; Jenny R Roberts; Aaron D Erdely; Patti C Zeidler-Erdely
Journal:  J Immunol Methods       Date:  2007-12-17       Impact factor: 2.303

10.  Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis.

Authors:  Fernando A Bozza; Jorge I Salluh; André M Japiassu; Marcio Soares; Edson F Assis; Rachel N Gomes; Marcelo T Bozza; Hugo C Castro-Faria-Neto; Patrícia T Bozza
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  10 in total
  2 in total

1.  Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Authors:  Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  Viruses       Date:  2015-03-10       Impact factor: 5.048

2.  Optimization of multiplex quantitative polymerase chain reaction based on response surface methodology and an artificial neural network-genetic algorithm approach.

Authors:  Ping Pan; Weifeng Jin; Xiaohong Li; Yi Chen; Jiahui Jiang; Haitong Wan; Daojun Yu
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.